Gene targeting strategy for B-CAG-luc Hep 3B(v2) . The luciferase cDNA sequence with CAG promoter was inserted in the AAVS1 locus exon1 of wild-type Hep 3B.
The luminescence signal intensity of B-CAG-luc Hep 3B (v2) cells. The luminescence intensity was detected by Bright-GloTM luciferase Assay System (Promega, Cat E2610), and B-CAG-luc Hep 3B (v2) cells have strong luminescence signal.
Tumor Growth Curve & Body Weight Changes
Subcutaneous xenograft tumor growth of B-CAG-luc Hep 3B (v2) cells. B-CAG-luc Hep 3B (v2) cells and wild-type Hep 3B cells (8×106) were subcutaneously implanted into the B-NDG mice (n=4).Tumor size and mice body weight were measured twice a week. (A) Tumor average volume ± SEM, (B) Mice body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5a X b2, where a and b were the long and short diameters of the tumor, respectively. As shown in panel A, B-CAG-luc Hep 3B (v2) were able to establish tumor in vivo and can be used for efficacy study.
In vivo Imaging Analysis
Tumor growth and in vivo imaging of B-CAG-luc Hep 3B (v2) cells. B-CAG-luc Hep 3B (v2) and wild-type Hep 3B(8×106) were injected by tail vein into B-NDG mice (n=?). Signal intensity was measured twice a week. (A) Imaging was performed on days 0, 3, 7, 10, 14, 17, 21, 24, 28, 31, 35 and 38, (B)Tumor signal intensity changes. B-CAG-luc Hep 3B (v2) cells can be used for in vivo efficacy evaluation.